Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Amryt Pharma signs fifth distribution deal in three months, appoints new head of Europe

The agreement, covering Lebanon, Jordan and Syria, is with Pharaon Healthcare-Droguerie Mercury S.A.L, a full service distributor in pharmaceuticals
Lojuxta is a therapy used to treat adult patients with HoFH, a rare, life-threatening, genetic cholesterol disorder

Amryt Pharma PLC (LON:AMYT) shares gained 6% on Tuesday after news the firm signed its fifth new distribution deal in approximately three months for Lojuxta, which is used to treat a rare life-threatening disease.

The agreement, covering Lebanon, Jordan and Syria, is with Pharaon Healthcare-Droguerie Mercury S.A.L , a full service distributor in pharmaceuticals.

READ: Amryt Pharma inks fourth distribution deal in three months for key product

Lojuxta is a therapy used to treat adult patients with HoFH, a genetic cholesterol disorder.

The AIM-listed company said that there are approximately 40 patients with HoFH in the countries covered by this agreement, with Lebanon in particular having a pronounced ‘founder effect.”

Dr. Joe Wiley, Amryt's chief executive officer, said: “This new agreement should help to ensure we can respond effectively to physicians’ requests regarding their patients suffering with HoFH.”

In a separate statement, Amryt Pharma also announced the appointment of Jordi Casals as the company’s head of Europe.

Casals, who has over 20 years’ experience in the pharmaceutical and biotech industry, will be responsible for leading and further developing Amryt’s European operations, including product launches.

The company said his initial focus will be on the continuing sales growth of the firm’s commercial asset, Lojuxta.

Wiley said: “His significant commercial experience of European markets will help us to drive and further develop Amryt’s growth across this key region.”

In afternoon trading, Amryt Pharma shares were 6.2% higher at 20.25p.

 -- Adds share price --

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use